$44.01 Million in Sales Expected for Cardlytics Inc (CDLX) This Quarter

Equities research analysts predict that Cardlytics Inc (NASDAQ:CDLX) will post sales of $44.01 million for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Cardlytics’ earnings, with estimates ranging from $43.56 million to $44.58 million. Cardlytics posted sales of $39.27 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 12.1%. The firm is scheduled to announce its next quarterly earnings results on Monday, March 18th.

On average, analysts expect that Cardlytics will report full year sales of $147.08 million for the current year, with estimates ranging from $146.43 million to $148.00 million. For the next year, analysts anticipate that the business will post sales of $198.02 million, with estimates ranging from $184.00 million to $210.12 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Cardlytics.

Cardlytics (NASDAQ:CDLX) last released its earnings results on Tuesday, November 13th. The company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.48. The business had revenue of $34.58 million for the quarter, compared to the consensus estimate of $37.62 million. The company’s revenue for the quarter was up 10.1% on a year-over-year basis.

A number of equities research analysts have recently commented on CDLX shares. SunTrust Banks reiterated a “buy” rating and set a $27.00 target price on shares of Cardlytics in a research note on Tuesday, September 11th. JPMorgan Chase & Co. lowered their price objective on Cardlytics from $31.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 14th. Zacks Investment Research cut Cardlytics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 21st. Raymond James lowered their price objective on Cardlytics from $23.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 14th. Finally, Morgan Stanley lowered their price objective on Cardlytics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 14th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $23.25.

NASDAQ CDLX opened at $14.50 on Tuesday. The firm has a market cap of $291.40 million and a PE ratio of -1.81. Cardlytics has a one year low of $11.10 and a one year high of $28.29. The company has a current ratio of 3.04, a quick ratio of 3.04 and a debt-to-equity ratio of 0.91.

In related news, Director Polaris Venture Management Co. sold 150,000 shares of the business’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $25.04, for a total value of $3,756,000.00. The sale was disclosed in a legal filing with the SEC, which is available through this link.

A number of hedge funds have recently bought and sold shares of CDLX. Wells Fargo & Company MN grew its holdings in Cardlytics by 72.4% during the 3rd quarter. Wells Fargo & Company MN now owns 8,004 shares of the company’s stock valued at $201,000 after buying an additional 3,361 shares in the last quarter. TIAA CREF Investment Management LLC purchased a new position in Cardlytics during the 3rd quarter valued at about $202,000. Schwab Charles Investment Management Inc. purchased a new position in Cardlytics during the 2nd quarter valued at about $214,000. Rockefeller Capital Management L.P. purchased a new position in Cardlytics during the 3rd quarter valued at about $231,000. Finally, Teachers Advisors LLC purchased a new position in Cardlytics during the 3rd quarter valued at about $263,000. 58.58% of the stock is owned by institutional investors and hedge funds.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Recommended Story: What is an investor looking for in an SEC filing?

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit